Pharmacophore modeling and 3D-QSAR studies of leucettines as potent Dyrk2 inhibitors

Bharate SB, Yadav RR, Battula S, Vishwakarma RA (2012a) Meridianins: marine-derived potent kinase inhibitors. Mini Rev Med Chem 12:618–631

Bharate SB, Manda S, Mupparapu N, Battini N, Vishwakarma RA (2012b) Chemistry and biology of fascaplysin, a potent marine-derived CDK-4 inhibitor. Mini Rev Med Chem 12:650–664

Bharate SB, Manda S, Joshi P, Singh B, Vishwakarma RA (2012c) Total synthesis and anti-cholinesterase activity of marine-derived bis-indole alkaloid fascaplysin. Med Chem Commun 3:1098–1103

Bharate SB, Yadav RR, Vishwakarma RA (2013a) QSAR and pharmacophore study of Dyrk1A inhibitory meridianin analogs as potential agents for treatment of neurodegenerative diseases. Med Chem 9:152–161

Bharate SB, Singh B, Bharate JB, Jain SK, Meena S, Vishwakarma RA (2013b) QSAR and pharmacophore modeling of N-acetyl-2-aminobenzothiazole class of phosphoinositide-3-kinase-alpha inhibitors. Med Chem Res 22:890–899

Cuny GD, Robin M, Ulyanova NP, Patnaik D, Pique V, Casano G, Liu J-F, Lin X, Xian J, Glicksman MA, Stein RL, Higgins JMG (2010) Structure–activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors. Bioorg Med Chem Lett 20:3491–3494

Cuny GD, Ulyanova NP, Patnaik D, Liu J-F, Lin X, Auerbach K, Ray SS, Xian J, Glicksman MA, Stein RL, Higgins JM (2012) Structure–activity relationship study of beta-carboline derivatives as haspin kinase inhibitors. Bioorg Med Chem Lett 22:2015–2019

Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, Filippakopoulos P, Lozach O, Babault L, Tahtouh T, Baratte B, Ogawa Y, Hagiwara M, Eisenreich A, Rauch U, Knapp S, Meijer L, Bazureau JP (2011) Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem 54:4172–4186

Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA (2006a) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20:647–671

Dixon SL, Smondyrev AM, Rao SN (2006b) PHASE: a novel approach to pharmacophore modeling and 3D database searching. Chem Biol Drug Des 67:370–372

Ferrer I, Barrachina M, Puig B, Lagran MMD, Marti E, Avila J, Dierssen M (2005) Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis 20:392–400

Filippakopoulos P, Myrianthopoulos V, Kritsanida M, Magiatis P, Skaltsounis AL, Krojer T, Gileadi O, Hapka E, Fedorov O, Berridge G, Wang J, Shrestha L, Vollmar M, Von Delft F, Arrowsmith CH, Edwards A, Weigelt J, Bountra C, Mikros E, Knapp S (2010) Crystal structure of dual-specificity tyrosine phosphorylation regulated kinase 2 (Dyrk2) in complex with an indirubin ligand. RCSB. doi: 10.2210/pdb3kvw/pdb

Laguna A, Aranda S, Barallobre MJ, Barhoum R, Fernández E, Fotaki V, Delabar JM, de la Luna S, de la Villa P, Arbonés ML (2008) The protein kinase DYRK1A regulates caspase-9-mediated apotposis during retina development. Dev Cell 15:841–853

Lochhead PA, Sibbet G, Morrice N, Cleghon V (2005) Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs. Cell 121:925–936

Maddika S, Chen J (2009) Protein kinase Dyrk2 is a scaffold that facilitates assembly of an E3 ligase. Nat Cell Biol 11:409–419

Miller CT, Aggarwal S, Lin TK, Dagenais SL, Contreras JI, Orringer MB, Glover TW, Beer DG, Lin L (2003) Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas. Cancer Res 63:4136–4143

Park J, Song WJ, Chung KC (2009) Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell Mol Life Sci 66:3235–3240

Tahtouh T, Elkins JM, Filippakopoulos P, Soundararajan M, Burgy G, Durieu E, Cochet C, Schmid RS, Lo DC, Delhommel F, Oberholzer AE, Pearl LH, Carreaux F, Bazureau JP, Knapp S, Meijer L (2012) Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J Med Chem 55:9312–9330

Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K (2007) Dyrk2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell 25:725–738

Yamashita S, Chujo M, Moroga T, Anami K, Tokuishi K, Miyawaki M, Kawano Y, Takeno S, Yamamoto S, Kawahara K (2009) Dyrk2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer. Anticancer Res 29:2753–2757

Yoshida K (2008) Role for Dyrk family kinases on regulation of apoptosis. Biochem Pharmacol 76:1389–1394